Close menu


  • Data on 76 patients with gastrointestinal acute Graft-versus-Host Disease treated with MaaT013 published in eClinicalMedicine, one of The Lancet Discovery Science suite’s journals


  •  Ongoing Phase 3 trial built on positive data from Phase 2 HERACLES study and ongoing early access program (EAP) in France: both datasets showed that MaaT013 was welltolerated in immunocompromised patients and had promising clinical benefits




Lyon, France, July 26, 2023, 6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that eClinicalMedicine has published clinical data on MaaT013 as a treatment for acute Graft-versus-Host Disease (aGvHD). The data includes results from 24 patients in a Phase 2 clinical trial and 52 patients enrolled in the Early Access Program (EAP) in France. The article entitled “Pooled allogeneic faecal microbiota MaaT013 for steroidrefractory gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial” can be accessed here.



Read the press release


More information